What is NephroPlus?
NephroPlus operates as India's largest network of dialysis centers, fundamentally transforming the delivery of renal care. By prioritizing clinical quality and patient experience, the company has successfully mitigated the traditional stressors associated with chronic kidney disease management. Its market position is characterized by a robust operational footprint and a commitment to standardized, high-quality care protocols that have set a benchmark for the industry. The company leverages advanced medical technology and a scalable service model to address the growing demand for accessible dialysis solutions, effectively bridging the gap between clinical necessity and patient convenience.
How much funding has NephroPlus raised?
NephroPlus has raised a total of $155.1M across 5 funding rounds:
Series A
$4.3M
Series B
$10M
Series C
$15M
Series E
$24M
Series F
$101.8M
Series A (2011): $4.3M with participation from Bessemer Venture Partners
Series B (2014): $10M led by Bessemer Venture Partners and International Finance Corporation
Series C (2016): $15M supported by SeaLink Capital Partners and International Finance Corp
Series E (2021): $24M featuring Investcorp, IIFL Asset Management, and Bessemer Venture Partners
Series F (2024): $101.8M backed by Quadria Capital Investment Management
Key Investors in NephroPlus
Quadria Capital Investment Management
A leading private equity firm based in India and Singapore, focused on transforming healthcare in Asia through strategic investments in scalable healthcare companies.
Bessemer Venture Partners
A prominent venture capital firm with a long-standing history of supporting high-growth companies across diverse sectors, including healthcare and technology.
International Finance Corporation
A multilateral financial institution dedicated to mobilizing capital and expertise for sustainable development and private sector growth in emerging markets.
What's next for NephroPlus?
Following the latest capital injection, NephroPlus is positioned to accelerate its strategic initiatives, likely focusing on geographic expansion and the integration of next-generation renal care technologies. The company's ability to secure major enterprise-level funding suggests a focus on deepening its market penetration and enhancing its digital health infrastructure. As the firm continues to scale, the emphasis will likely remain on operational efficiency and the maintenance of its high-quality care standards, ensuring that it remains the preferred partner for both patients and healthcare stakeholders in the evolving Asian medical landscape.
See full NephroPlus company page